HIGHLIGHTS
- who: Migraine Cranial autonomic symptoms and collaborators from the Via della Pisana, Rome, Italy have published the research: Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial, in the Journal: (JOURNAL)
- what: Designed as a conventional acute intervention during a moderate-tosevere migraine attack, this study shows that rizatriptan is consistently more effective than placebo in achieving pain freedom at 2 h and total migraine freedom at 2 h in patients with UAs. Despite its strong point as a randomized, double-blind, placebo-controlled pharmacological trial in migraine patients with UAs, the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.